Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Zanolimumab · MDX-016

Monoclonal antibody · Antagonist of CD4 · developed by Emergent BioSolutions

Phase 2/3 Most advanced trial (none active)
EBS Developer
1 Registered trials

What is Zanolimumab?

Zanolimumab is a human IgG1 monoclonal antibody that binds CD4 on T cells, preventing CD4-MHC class II interaction and blocking T cell activation. It induces antibody-dependent cellular cytotoxicity against CD4-expressing tumor cells. It is studied in T cell lymphomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MDX-016, HuMax-CD4
Drug type
Monoclonal antibody
Targets
CD4, MHC class II (binding partner it blocks)
Mechanism
Antagonist of CD4
Pathways
T cell activation
Therapy area
Oncology
Developer
Emergent BioSolutions (EBS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
HG3L8885M0

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00877656 Phase 2/3 T Cell Lymphoma Completed EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

T Cell Lymphoma

Other drugs acting on CD4

Anti-Thymocyte Globulin FDA approved

More from Emergent BioSolutions

AIGIV FDA approved Bacillus anthracis strain V770-NP1-R antigens FDA approved Brincidofovir FDA approved smallpox vaccine live, New York City Board of Health vaccinia strain FDA approved Vaccinia Immune Globulin FDA approved Ad4-EnvC150 Phase 1 Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 AV7909 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind Zanolimumab

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.